Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort.

Pellegrini C, Botta F, Massi D, Martorelli C, Facchetti F, Gandini S, Maisonneuve P, Avril MF, Demenais F, Bressac-de Paillerets B, Hoiom V, Cust AE, Anton-Culver H, Gruber SB, Gallagher RP, Marrett L, Zanetti R, Dwyer T, Thomas NE, Begg CB, Berwick M, Puig S, Potrony M, Nagore E, Ghiorzo P, Menin C, Manganoni AM, Rodolfo M, Brugnara S, Passoni E, Sekulovic LK, Baldini F, Guida G, Stratigos A, Ozdemir F, Ayala F, Fernandez-de-Misa R, Quaglino P, Ribas G, Romanini A, Migliano E, Stanganelli I, Kanetsky PA, Pizzichetta MA, García-Borrón JC, Nan H, Landi MT, Little J, Newton-Bishop J, Sera F, Fargnoli MC, Raimondi S; IMI Study Group; GEM Study Group; M-SKIP Study Group.

Lancet Child Adolesc Health. 2019 May;3(5):332-342. doi: 10.1016/S2352-4642(19)30005-7. Epub 2019 Mar 12.

PMID:
30872112
2.

MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project.

Pasquali E, García-Borrón JC, Fargnoli MC, Gandini S, Maisonneuve P, Bagnardi V, Specchia C, Liu F, Kayser M, Nijsten T, Nagore E, Kumar R, Hansson J, Kanetsky PA, Ghiorzo P, Debniak T, Branicki W, Gruis NA, Han J, Dwyer T, Blizzard L, Landi MT, Palmieri G, Ribas G, Stratigos A, Council ML, Autier P, Little J, Newton-Bishop J, Sera F, Raimondi S; M-SKIP Study Group.

Int J Cancer. 2015 Feb 1;136(3):618-31. doi: 10.1002/ijc.29018. Epub 2014 Jun 18.

3.

Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study.

Fargnoli MC, Altobelli E, Keller G, Chimenti S, Höfler H, Peris K.

Melanoma Res. 2006 Apr;16(2):175-82.

PMID:
16567973
4.

MC1R variants as melanoma risk factors independent of at-risk phenotypic characteristics: a pooled analysis from the M-SKIP project.

Tagliabue E, Gandini S, Bellocco R, Maisonneuve P, Newton-Bishop J, Polsky D, Lazovich D, Kanetsky PA, Ghiorzo P, Gruis NA, Landi MT, Menin C, Fargnoli MC, García-Borrón JC, Han J, Little J, Sera F, Raimondi S.

Cancer Manag Res. 2018 May 14;10:1143-1154. doi: 10.2147/CMAR.S155283. eCollection 2018.

5.

Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color.

Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, Willemze R, Bavinck JN.

J Invest Dermatol. 2001 Aug;117(2):294-300.

6.

MC1R genotypes and risk of melanoma before age 40 years: a population-based case-control-family study.

Cust AE, Goumas C, Holland EA, Agha-Hamilton C, Aitken JF, Armstrong BK, Giles GG, Kefford RF, Schmid H, Hopper JL, Mann GJ, Jenkins MA.

Int J Cancer. 2012 Aug 1;131(3):E269-81. doi: 10.1002/ijc.27357. Epub 2012 Jan 30.

7.

MC1R: three novel variants identified in a malignant melanoma association study in the Spanish population.

Fernandez L, Milne R, Bravo J, Lopez J, Avilés J, Longo M, Benítez J, Lázaro P, Ribas G.

Carcinogenesis. 2007 Aug;28(8):1659-64. Epub 2007 Apr 13.

PMID:
17434924
8.

Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries.

Goldstein AM, Chaudru V, Ghiorzo P, Badenas C, Malvehy J, Pastorino L, Laud K, Hulley B, Avril MF, Puig-Butille JA, Miniere A, Marti R, Chompret A, Cuellar F, Kolm I, Mila M, Tucker MA, Demenais F, Bianchi-Scarra G, Puig S, de-Paillerets BB.

Int J Cancer. 2007 Aug 15;121(4):825-31.

9.

Melanocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population.

Stratigos AJ, Dimisianos G, Nikolaou V, Poulou M, Sypsa V, Stefanaki I, Papadopoulos O, Polydorou D, Plaka M, Christofidou E, Gogas H, Tsoutsos D, Kastana O, Antoniou C, Hatzakis A, Kanavakis E, Katsambas AD.

J Invest Dermatol. 2006 Aug;126(8):1842-9. Epub 2006 Apr 6.

10.

MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population.

Landi MT, Kanetsky PA, Tsang S, Gold B, Munroe D, Rebbeck T, Swoyer J, Ter-Minassian M, Hedayati M, Grossman L, Goldstein AM, Calista D, Pfeiffer RM.

J Natl Cancer Inst. 2005 Jul 6;97(13):998-1007. Erratum in: J Natl Cancer Inst. 2005 Sep 21;97(18):1385.

PMID:
15998953
11.

Population-based study of natural variation in the melanocortin-1 receptor gene and melanoma.

Kanetsky PA, Rebbeck TR, Hummer AJ, Panossian S, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Culver HA, Zanetti R, Gallagher RP, Dwyer T, Busam K, From L, Mujumdar U, Wilcox H, Begg CB, Berwick M.

Cancer Res. 2006 Sep 15;66(18):9330-7.

12.

Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer.

Bauer J, Weng J, Kebebew E, Soares P, Trovisco V, Bastian BC.

Exp Dermatol. 2009 Jun;18(6):548-52. doi: 10.1111/j.1600-0625.2008.00827.x.

13.

MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project.

Tagliabue E, Fargnoli MC, Gandini S, Maisonneuve P, Liu F, Kayser M, Nijsten T, Han J, Kumar R, Gruis NA, Ferrucci L, Branicki W, Dwyer T, Blizzard L, Helsing P, Autier P, García-Borrón JC, Kanetsky PA, Landi MT, Little J, Newton-Bishop J, Sera F, Raimondi S; M-SKIP Study Group.

Br J Cancer. 2015 Jul 14;113(2):354-63. doi: 10.1038/bjc.2015.231. Epub 2015 Jun 23.

14.

CDKN2A and MC1R variants found in Cypriot patients diagnosed with cutaneous melanoma.

Koulermou G, Shammas C, Vassiliou A, Kyriakides TC, Costi C, Neocleous V, Phylactou LA, Pantelidou M.

J Genet. 2017 Mar;96(1):155-160.

15.

Sporadic melanoma in South-Eastern Italy: the impact of melanocortin 1 receptor (MC1R) polymorphism analysis in low-risk people and report of three novel variants.

Guida S, Bartolomeo N, Zanna PT, Grieco C, Maida I, De Summa S, Tommasi S, Guida M, Azzariti A, Foti C, Filotico R, Guida G.

Arch Dermatol Res. 2015 Aug;307(6):495-503. doi: 10.1007/s00403-015-1552-4. Epub 2015 Mar 4.

PMID:
25736238
16.

Melanocortin receptor 1 variants and melanoma risk: a study of 2 European populations.

Scherer D, Nagore E, Bermejo JL, Figl A, Botella-Estrada R, Thirumaran RK, Angelini S, Hemminki K, Schadendorf D, Kumar R.

Int J Cancer. 2009 Oct 15;125(8):1868-75. doi: 10.1002/ijc.24548.

17.

CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.

Pastorino L, Bonelli L, Ghiorzo P, Queirolo P, Battistuzzi L, Balleari E, Nasti S, Gargiulo S, Gliori S, Savoia P, Abate Osella S, Bernengo MG, Bianchi Scarrà G.

Pigment Cell Melanoma Res. 2008 Dec;21(6):700-9. doi: 10.1111/j.1755-148X.2008.00512.x. Epub 2008 Oct 22.

PMID:
18983535
18.

Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype?

Palmer JS, Duffy DL, Box NF, Aitken JF, O'Gorman LE, Green AC, Hayward NK, Martin NG, Sturm RA.

Am J Hum Genet. 2000 Jan;66(1):176-86.

19.
20.

Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma.

Vernali S, Waxweiler WT, Dillon PM, Kanetsky PA, Orlow I, Luo L, Busam KJ, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Gallagher RP, Zanetti R, Rosso S, Sacchetto L, Dwyer T, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group.

JAMA Dermatol. 2017 Oct 1;153(10):1026-1031. doi: 10.1001/jamadermatol.2017.2444.

Supplemental Content

Support Center